ReviewCurrent opinion in oncology2020
Challenges and opportunities in the management of metastatic renal cell carcinoma: combination therapy and the role of cytoreductive surgery.
Review in Current opinion in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Co-delivery of axitinib and PD-L1 siRNA for the synergism of vascular normalization and immune checkpoint inhibition to boost anticancer immunity.Journal of nanobiotechnology · 2025Article
- The role of RNA-modifying proteins in renal cell carcinoma.Cell death & disease · 2024Review
- A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials.Pharmaceutical medicine · 2023Article
- Early Integration of Palliative Care for Patients Receiving Systemic Immunotherapy for Renal Cell Carcinoma.Journal of cancer immunology · 2023Article
- Combination immunotherapy in a patient with hemodialysis therapy and metachronous bilateral clear cell renal cell carcinoma: Case report and literature review.Urology case reports · 2022Article
- Pharmacologic Therapies for Non-Muscle Invasive Bladder Cancer: Current and Future Treatments.Archives of pharmacology and therapeutics · 2022Article
- Renal Cell Carcinoma with Cardiac Metastases: A Case Report and Review of the Literature.Journal of kidney cancer and VHL · 2022Article
- A 25 year perspective on the evolution and advances in an understanding of the biology, evaluation and treatment of kidney cancer.Urologic oncology · 2021Review
- Article
- A challenging frontier - the genomics and therapeutics of nonclear cell renal cell carcinoma.Current opinion in oncology · 2021Review
- Gastrointestinal Metastases From Primary Renal Cell Cancer: A Single Center Review.Frontiers in oncology · 2021Article
- Taking a SPOP at renal cell carcinoma - unraveling a novel pathway for Tumor progression in clear cell RCC.EBioMedicine · 2020Article
- To Be or "Node" to Be: Nodal Disease and the Role of Lymphadenectomy in the Treatment of Renal Cell Carcinoma.Medical research archives · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewAs the biology of metastatic renal cell carcinoma (mRCC) continues to be elucidated, novel treatments focused around immunotherapies and targeted therapies will continue to emerge. In this review, we will highlight recent treatment advances and their implications for surgical and systemic therapy. RECENT
findingsSeveral new treatments, including the tyrosine kinase inhibitor cabozantinib, the combination of a programmed cell death protein 1 antibody (nivolumab) with a cytotoxic T-lymphocyte-associated antigen 4 antibody (ipilimumab), and the combination of axitinib with pembrolizumab or avelumab have been approved by the US Food and Drug Administration as first-line therapy for the treatment of mRCC. Although promising survival benefits have been seen with these new therapies, careful patient selection is still critical. SUMMARY: The introduction of novel therapies and the investigation of combinatorial therapies have shifted the treatment paradigm for advanced RCC. Present trials have provided promising data that could lead to further therapeutic advances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.